Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.
OBJECTIVE
We evaluate terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome.


METHODS
The study included 100, 20 to-50-year-old subjects who met the consensus criteria for chronic prostatitis/chronic pelvic pain syndrome and had not received previous alpha-blockers. Subjects were randomized to receive terazosin with dose escalation from 1 to 5 mg. daily or placebo for 14 weeks. The primary criterion for response was scoring 2 or less ("delighted-to-mostly satisfied") on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) quality of life item. The secondary criterion for response was greater than 50% reduction in NIH-CPSI pain score at 14 weeks. Other outcomes included total and NIH-CPSI domain scores, International Prostate Symptom Score, peak urinary flow rate, post-void residual urine and adverse effects.


RESULTS
Using the primary criterion 24 of 43 evaluable subjects (56%) responded in the terazosin group compared to 14 of 43 (36%) in the placebo group (p = 0.03). Using the secondary criterion 26 of 43 subjects (60%) responded in the terazosin group compared to 16 of 43 (37%) in the placebo group (p = 0.03). The terazosin group had greater reductions (p <0.05) in NIH-CPSI total score, individual domain scores and International Prostate Symptom Score than the placebo group. There was no difference in peak urinary flow rate or post-void residual. In the terazosin group 18 patients (42%) had side effects compared to 9 (21%) in the placebo group (p = 0.04).


CONCLUSIONS
Terazosin proved superior to placebo for patients with chronic prostatitis/chronic pelvic pain syndrome who had not received alpha-blockers previously.
Cheah
Phaik Yeong
PY
School of Pharmaceutical Sciences, University of Science Malaysia, Penang, Malaysia.
Liong
Men Long
ML
Yuen
Kah Hay
KH
Teh
Chu Leong
CL
Khor
Timothy
T
Yang
Jin Rong
JR
Yap
Hin Wai
HW
Krieger
John N
JN
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D002908:Chronic Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D017699:Pelvic Pain / Q000188:drug therapy* / Q000209:etiology; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011472:Prostatitis / Q000150:complications / Q000188:drug therapy*; D013577:Syndrome
D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin